BIOMARKER DRIVEN TARGETED THERAPY FOR LATE-RECURRING ER-POSITIVE BREAST CANCER

$1,772,964FY2019Defense Health AgencyDOD

The Leland Stanford Junior University

Investigators

View source on USAspending →